Anderson JL, Gutmann DH. Neurofibromatosis type 1. Handb Clin Neurol. 2015;132:75–86.

Article  PubMed  Google Scholar 

Martin GA, et al. The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21. Cell. 1990;63:843–9.

Article  CAS  PubMed  Google Scholar 

Basu TN, et al. Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature. 1992;356:713–5.

Article  CAS  PubMed  Google Scholar 

DeClue JE, et al. Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis. Cell. 1992;69:265–73.

Article  CAS  PubMed  Google Scholar 

Trovó-Marqui A, Tajara E. Neurofibromin: a general outlook. Clin Genet. 2006;70:1–13.

Article  PubMed  Google Scholar 

Gutmann DH, et al. Neurofibromatosis type 1. Nat Rev Dis Primer. 2017;3:17004.

Article  Google Scholar 

Spyk SL, Thomas N, Cooper DN, Upadhyaya M. Neurofibromatosis type 1-associated tumours: their somatic mutational spectrum and pathogenesis. Hum Genomics. 2011;5:623–90.

Article  CAS  PubMed Central  Google Scholar 

Le LQ, et al. Susceptible stages in Schwann cells for NF1-associated plexiform neurofibroma development. Cancer Res. 2011;71:4686–95.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhu Y, Ghosh P, Charnay P, Burns DK, Parada LF. Neurofibromas in NF1: Schwann cell origin and role of tumor environment. Science. 2002;296:920–2.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Packer RJ, et al. Implications of new understandings of gliomas in children and adults with NF1: report of a consensus conference. Neuro-Oncol. 2020;22:773–84.

Article  PubMed  PubMed Central  Google Scholar 

Kresbach C, et al. Atypical neurofibromas reveal distinct epigenetic features with proximity to benign peripheral nerve sheath tumor entities. Neuro-Oncol. 2023;25:1644–55.

Article  CAS  PubMed  PubMed Central  Google Scholar 

• Rhodes SD, et al. Cdkn2a (Arf) loss drives NF1-associated atypical neurofibroma and malignant transformation. Hum Mol Genet. 2019;28:2752–62. (This is an important study that defines the molecular mechanisms underlying malignant transformation of NF-1-associated plexiform neurofibromas to malignant peripheral nerve sheath tumors.)

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tong S, Devine WP, Shieh JT. Tumor and constitutional sequencing for neurofibromatosis type 1. JCO Precis Oncol. 2022;6:e2100540.

Article  PubMed  PubMed Central  Google Scholar 

Mitchell DK, et al. Spatial gene expression profiling unveils immuno-oncogenic programs of NF1-associated peripheral nerve sheath tumor progression. Clin Cancer Res Off J Am Assoc Cancer Res. 2023. https://doi.org/10.1158/1078-0432.CCR-23-2548.

Article  Google Scholar 

Kahen EJ, et al. Neurofibromin level directs RAS pathway signaling and mediates sensitivity to targeted agents in malignant peripheral nerve sheath tumors. Oncotarget. 2018;9:22571–85.

Article  PubMed  PubMed Central  Google Scholar 

Simanshu DK, Nissley DV, McCormick F. RAS proteins and their regulators in human disease. Cell. 2017;170:17–33.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dombi E, et al. Activity of selumetinib in neurofibromatosis type 1-related plexiform neurofibromas. N Engl J Med. 2016;375:2550–60.

Article  CAS  PubMed  PubMed Central  Google Scholar 

• Gross AM, et al. Selumetinib in children with inoperable plexiform neurofibromas. N Engl J Med. 2020;382:1430–42. (This clinical trial evaluating the efficacy of the MEK inhibitor selumetinib led to the FDA approval of selumetinib for symptomatic, inoperable plexiform neurofibromas in NF-1 pediatric patients.)

Article  CAS  PubMed  PubMed Central  Google Scholar 

O’Sullivan Coyne GH, et al. Phase II trial of the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886 Hydrogen Sulfate) in adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN). J Clin Oncol. 2020;38:3612–3612.

Article  Google Scholar 

Bendell JC, et al. A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor. Br J Cancer. 2017;116:575–83.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fangusaro J, et al. Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial. Lancet Oncol. 2019;20:1011–22.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ma Y, et al. A molecular basis for neurofibroma-associated skeletal manifestations in NF1. Genet Med Off J Am Coll Med Genet. 2020;22:1786–93.

CAS  Google Scholar 

Walsh KS, et al. Impact of MEK inhibitor therapy on neurocognitive functioning in NF1. Neurol Genet. 2021;7:e616.

Article  PubMed  PubMed Central  Google Scholar 

Ciruela A, et al. Identification of MEK1 as a novel target for the treatment of neuropathic pain. Br J Pharmacol. 2003;138:751–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ji RR, Baba H, Brenner GJ, Woolf CJ. Nociceptive-specific activation of ERK in spinal neurons contributes to pain hypersensitivity. Nat Neurosci. 1999;2:1114–9.

Article  CAS  PubMed  Google Scholar 

Song Y, et al. Targeting RAS–RAF–MEK–ERK signaling pathway in human cancer: Current status in clinical trials. Genes Dis. 2022;10:76–88.

Article  PubMed  PubMed Central  Google Scholar 

Degirmenci U, Yap J, Sim YRM, Qin S, Hu J. Drug resistance in targeted cancer therapies with RAF inhibitors. Cancer Drug Resist. 2021;4:665–83.

CAS  PubMed  PubMed Central  Google Scholar 

• Kilburn LB, et al. The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial. Nat Med. 2024;30:207–17. (This is an important clinical trial demonstrating response in heavily pre-treated pediatric patients with BRAF-altered low-grade glioma that has implications for patients with NF1-associated low-grade gliomas.)

Article  CAS  PubMed  Google Scholar 

Sigaud R, et al. The first-in-class ERK inhibitor ulixertinib shows promising activity in mitogen-activated protein kinase (MAPK)-driven pediatric low-grade glioma models. Neuro-Oncol. 2022;25:566–79.

Article  PubMed Central  Google Scholar 

Flint AC, et al. Combined CDK4/6 and ERK1/2 inhibition enhances antitumor activity in NF1-associated plexiform neurofibroma. Clin Cancer Res. 2023;29:3438–56.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Boga SB, et al. MK-8353: Discovery of an orally bioavailable dual mechanism ERK inhibitor for oncology. ACS Med Chem Lett. 2018;9:761–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stathis A, et al. Results of an open-label phase 1b study of the ERK inhibitor MK-8353 plus the MEK inhibitor selumetinib in patients with advanced or metastatic solid tumors. Invest New Drugs. 2023;41:1–11.

Article  Google Scholar 

Bok S, et al. MEKK2 mediates aberrant ERK activation in neurofibromatosis type I. Nat Commun. 2020;11:5704.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang Y, Li S, Wang Y, Zhao Y, Li Q. Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective. Signal Transduct Target Ther. 2022;7:1–36.

CAS  Google Scholar 

Ferguson MJ, et al. Preclinical evidence for the use of sunitinib malate in the treatment of plexiform neurofibromas. Pediatr Blood Cancer. 2016;63:206–13.

Article  CAS  PubMed  Google Scholar 

Study Details | Study of Sutent®/Sunitinib (SU11248) in subjects with NF-1 plexiform neurofibromas | ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT01402817.

Robertson KA, et al. Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial. Lancet Oncol. 2012;13:1218–24.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kim A, et al. Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas. Pediatr Blood Cancer. 2013;60:396–401.

Article  CAS  PubMed  Google Scholar 

Solares I, Viñal D, Morales-Conejo M, Rodriguez-Salas N, Feliu J. Novel molecular targeted therapies for patients with neurofibromatosis type 1 with inoperable plexiform neurofibromas: a comprehensive review. ESMO Open. 2021;6:100223.

Article